## 2 Results and Discussion
### Antiproliferative Activity  
The compounds showed different activity against human cancer and normal cells at 10 \(\upmu\)M and 30 \(\upmu\)M concentrations. The analysis of activity on the cancer cell line showed a proportional decrease in viability in rapport with drug concentration, in most cases. Overall, cellular activity was lower than the control group. The untreated control group is considered as 100% mitochondrial viability as they represent cells with no treatment applied. A375 cells treated with **1a**, **1b**, **1c**, or **1d** at a 10 \(\upmu\)M concentration expressed a viability of 88.94 (\(\pm\)1.64)%, 118.00 (\(\pm\)2.94)% 100.76 (\(\pm\)2.80)%, or 99.98 (\(\pm\)6.71)%, respectively. A375 cells treated with **1a**, **1b**, **1c**, or **1d** at a 30 \(\upmu\)M concentration expressed a viability of 98.63 (\(\pm\)5.09)%, 92.49 (\(\pm\)10.46)%, 96.61 (\(\pm\)8.25)%, or 94.30 (\(\pm\)6.88)%, respectively. Compound 1a decreased viability by 9.69% for the 10 \(\upmu\)M concentration compared to the 30 \(\upmu\)M concentration. For the rest of the compounds, viability was decreased by 4.62%, 4.15%, or  
Figure 1: TG (red line)/DTG (black line) data recorded for synthesized triazoles, namely **1a** (**A**), **1b** (**B**), **1c** (**C**) and **1d** (**D**) in a dynamic air atmosphere at \(\beta\) = 10 \({}^{\circ}\)C\(\cdot\)min\({}^{-1}\). 5.67% more for the 30 \(\upmu\)M concentration than the 10 \(\upmu\)M concentration (Figure 2). Fibroblast analysis showed an increase in viability of 17-42% for a 10 \(\upmu\)M concentration and 28-81% for a 30 \(\upmu\)M concentration compared to the control group. Fibroblast analysis showed an increase in viability for most of the compounds tested. BJ cells treated with **1a**, **1b**, **1c**, or **1d** at a 10 \(\upmu\)M concentration expressed a viability of 117.96 (\(\pm\)7.81)%, 101.03 (\(\pm\)16.01)% 177.09 (\(\pm\)17.66)%, or 148.61 (\(\pm\)11.45)%, respectively. BJ cells treated with **1a**, **1b**, **1c**, or **1d** at a 30 \(\upmu\)M concentration expressed a viability of 168.67 (\(\pm\)16.16)%, 96.41 (\(\pm\)6.04)%, 196.90 (\(\pm\)21.07)%, or 122.14 (\(\pm\)4.12)%, respectively. Compounds 1a and 1c increased viability by 50.71% and 19.81%, respectively, for the 30 \(\upmu\)M concentration compared to the 10 \(\upmu\)M concentration. Compounds **1b** and **1d** increased viability by 4.61% and 26.47%, respectively for the 10 \(\upmu\)M concentration compared to the 30 \(\upmu\)M concentration (Figure 3). LDH assay results showed a decrease in cancer cell growth for the treated group, which resulted in lower LDH release compared with untreated control. Untreated cancer cells released 0.117 (\(\pm\)0.0059) U/mL LDH. A375 cells treated with **1a**, **1c**, or **1d** at a 10 \(\upmu\)M concentration released 0.106 (\(\pm\)0.0016) U/mL, 0.108 (\(\pm\)0.0026) U/mL, or 0.106 (\(\pm\)0.0062) U/mL LDH, respectively. A375 cells treated with **1a**, **1c**, or **1d** at a 10 \(\upmu\)M concentration released 0.109 (\(\pm\)0.0029) U/mL, 0.107 (\(\pm\)0.0068) U/mL, or 0.108 (\(\pm\)0.0026) U/mL LDH, respectively. Compound 1b was analyzed in another plate and had an untreated control value of 0.0584 U/mL and released 0.0497 U/mL. Compounds **1a**, **1b**, and **1d** decreased LDH release by 0.0026 U/mL, 0.00087U/mL, or 0.0021 U/mL, respectively for the 10 \(\upmu\)M concentration released 0.109 (\(\pm\)0.0029) U/mL, and 0.108 (\(\pm\)0.0026) U/mL, respectively. Compound 1b was analyzed  
concentration compared to the 30 \(\upmu\)M concentration, while **1c** decreased LDH release by 0.0008 U/mL for the 30 \(\upmu\)M concentration compared to the 10 \(\upmu\)M concentration. (Figure 4). Data showed a slight cell growth inhibition for treated groups, but higher compound concentration had an insignificant impact compared to a lower dose. Also, fibroblast showed little to no changes in LDH concentration. BJ cells had an untreated control value of 0.103 (\(\pm\)0.010) U/mL.